X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9314) 9314
Book Chapter (93) 93
Transcript (20) 20
Magazine Article (17) 17
Newspaper Article (14) 14
Newsletter (11) 11
Publication (4) 4
Book / eBook (3) 3
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7277) 7277
male (2702) 2702
female (2594) 2594
anticoagulants (2545) 2545
anticoagulants - therapeutic use (2469) 2469
hematology (2257) 2257
risk factors (2208) 2208
animals (2023) 2023
peripheral vascular disease (1719) 1719
aged (1603) 1603
middle aged (1570) 1570
rivaroxaban (1492) 1492
warfarin (1421) 1421
factor xa inhibitors (1419) 1419
thrombosis (1378) 1378
venous thromboembolism (1353) 1353
anticoagulants - adverse effects (1318) 1318
prevention (1230) 1230
treatment outcome (1198) 1198
pharmacology & pharmacy (1195) 1195
thromboembolism (1173) 1173
atrial fibrillation (1117) 1117
anticoagulants - administration & dosage (1108) 1108
administration, oral (1106) 1106
cardiac & cardiovascular systems (1064) 1064
adult (1060) 1060
stroke (1021) 1021
thrombin (1002) 1002
hemorrhage - chemically induced (966) 966
dabigatran (963) 963
care and treatment (932) 932
factor xa inhibitors - therapeutic use (909) 909
molecular-weight heparin (851) 851
analysis (848) 848
medicine & public health (836) 836
atrial fibrillation - drug therapy (820) 820
heparin (805) 805
coagulation (787) 787
blood coagulation - drug effects (779) 779
stroke - prevention & control (763) 763
health aspects (760) 760
research (759) 759
anticoagulation (734) 734
drug therapy (724) 724
anticoagulants - pharmacology (689) 689
apixaban (686) 686
time factors (682) 682
aged, 80 and over (680) 680
atrial fibrillation - complications (676) 676
deep-vein thrombosis (650) 650
factor xa inhibitor (630) 630
tissue factor (628) 628
fibrinolytic agents - therapeutic use (620) 620
surgery (616) 616
abridged index medicus (615) 615
mice (600) 600
risk (587) 587
medicine, general & internal (580) 580
enoxaparin (577) 577
mortality (573) 573
cardiology (564) 564
patients (564) 564
therapy (558) 558
management (557) 557
warfarin - therapeutic use (554) 554
bleeding (552) 552
risk-factors (551) 551
atrial-fibrillation (538) 538
risk assessment (517) 517
dose-response relationship, drug (516) 516
cancer (511) 511
hemorrhage (508) 508
safety (504) 504
proteins (495) 495
heparin - therapeutic use (491) 491
venous thromboembolism - prevention & control (490) 490
pharmacokinetics (489) 489
inflammation (486) 486
dosage and administration (484) 484
rivaroxaban - therapeutic use (483) 483
stroke - etiology (479) 479
double-blind (469) 469
factor xa (461) 461
review (461) 461
dabigatran etexilate (458) 458
internal medicine (457) 457
heparin, low-molecular-weight - therapeutic use (445) 445
thromboembolism - prevention & control (441) 441
factor xa inhibitors - adverse effects (434) 434
clinical trials (422) 422
pyrazoles - therapeutic use (420) 420
unfractionated heparin (418) 418
pyridones - therapeutic use (415) 415
cardiac arrhythmia (412) 412
antithrombotic therapy (410) 410
venous thromboembolism - drug therapy (410) 410
complications and side effects (409) 409
retrospective studies (409) 409
oral anticoagulants (408) 408
aspirin (407) 407
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9228) 9228
German (77) 77
French (58) 58
Spanish (37) 37
Japanese (32) 32
Russian (18) 18
Italian (16) 16
Polish (9) 9
Czech (8) 8
Chinese (7) 7
Swedish (7) 7
Portuguese (6) 6
Hungarian (5) 5
Danish (3) 3
Turkish (3) 3
Dutch (2) 2
Norwegian (2) 2
Lithuanian (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 635 - 641.e2
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 14, pp. 1326 - 1335
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2012, Volume 108, Issue 5, pp. 876 - 886
.... Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor... 
Recommendations | rivaroxaban | practical management | anticoagulant | Consensus Paper | Rivaroxaban | Anticoagulant | Practical management | ENOXAPARIN | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | recommendations | VENOUS THROMBOEMBOLISM | ANTITHROMBOTIC AGENTS | PHARMACOKINETICS | ASSAYS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Male | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Venous Thromboembolism - prevention & control | Benzimidazoles - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Venous Thrombosis - drug therapy | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Clinical Trials as Topic | Anticoagulants - adverse effects | Pregnancy | Practice Guidelines as Topic | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2015, Volume 2016, Issue 12, p. CD010957
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Journal Article